<DOC>
	<DOCNO>NCT00355576</DOCNO>
	<brief_summary>The objective study compare two combination drug , minocycline creatine celecoxib creatine , phase II trial design determine combination effective ALS .</brief_summary>
	<brief_title>Combination Therapy Selection Trial Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>Excess free radical , energy mishandling , excitotoxicity , activation cell death pathways inflammation likely contribute neurodegeneration ALS . Past trial may negative part test single agent , usually influence one mechanism cell death . Combinations agent affect different multiple mechanism neurodegeneration may necessary reach meaningful outcome trial ALS . This trial several unique feature . First , compare neuroprotective potential two combination agent impact multiple mechanism cell death . The combination minocycline/creatine celecoxib/creatine agent additive effect mouse model ALS , reduce neurodegeneration prolong survival individual agent alone . Second , use important new phase II selection trial design determine combination superior . Not trial test combination therapy , placebo , everyone enroll trial receive active treatment . Minocycline , creatine celecoxib test individually show safe patient ALS . This first time human trial conduct combination minocycline/creatine celecoxib/creatine . We compare combination drug phase II trial design determine combination superior . If successful , trial lead directly phase III trial select combination . If design find useful , trial lead large phase II selection trial assess great number agent simultaneously , thereby improve efficiency drug screening ALS .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>A clinical diagnosis possible , laboratorysupported probable , probable definite ALS , accord modify EL Escorial criterion FVC great equal 60 % screen visit Symptom onset within 5 year 21 85 year age If patient take riluzole , must stable dose least past thirty day A woman childbearing age , must nonlactating surgically sterile use effective method birth control ( barrier method ) negative pregnancy test Able maintain adequate hydration level define 68 cup ( 8ounces/cup ) water noncaffeinated beverage per day Willing able give sign informed consent approve Institutional Review Board ( IRB ) Tracheotomy mechanical ventilation Diagnosis neurodegenerative disease ( Parkinson 's disease , Alzheimer 's disease , etc ) Unstable medical illness ( coronary artery disease , advanced cancer , active esophageal gastroduodenal ulcer , etc ) last one year Systemic Lupus Erythematosis FVC &lt; 60 % Pregnancy lactation Allergy minocycline , tetracycline , celecoxib , sulfonamide , NSAIDS , creatine History congestive heart failure Renal disease [ baseline Cr &gt; 1.5 ( men ) 1.2 ( woman ) ] History significant hepatic disease ( baseline AST/ALT bilirubin &gt; 1.5x normal ) Use investigational agent within thirty day enrollment First degree relative ALS gene identify familial ALS Inability unwillingness maintain adequate daily hydration ( define ) Limited mental capacity patient provide write informed consent comply evaluation procedure . History recent alcohol drug abuse noncompliance treatment experimental protocol .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>Celecoxib</keyword>
	<keyword>Creatine</keyword>
	<keyword>Minocycline</keyword>
	<keyword>Combination</keyword>
	<keyword>Selection</keyword>
	<keyword>ALS</keyword>
	<keyword>Motor Neuron Disease</keyword>
</DOC>